[{"id":"09ded2a9-51fd-42d3-895d-cb939c45eb1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06106841","created_at":"2023-10-30T16:12:47.129Z","updated_at":"2024-07-02T16:35:31.239Z","phase":"Phase 1/2","brief_title":"TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)","source_id_and_acronym":"NCT06106841","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB3909"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/05/2023","start_date":" 10/05/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-30"},{"id":"75fb28e7-a73b-48f2-a150-9f064b4b9cf7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05959694","created_at":"2023-07-27T18:08:44.727Z","updated_at":"2024-07-02T16:35:32.458Z","phase":"Phase 1/2","brief_title":"A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .","source_id_and_acronym":"NCT05959694","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" PLCG2","pipe":"","alterations":" ","tags":["PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB3909"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-10-20"},{"id":"c3607658-7fe2-4d61-a41c-3828f23003a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05775575","created_at":"2023-03-20T20:03:29.705Z","updated_at":"2024-07-02T16:35:52.950Z","phase":"Phase 1/2","brief_title":"A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer","source_id_and_acronym":"NCT05775575","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB3909"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-03-20"},{"id":"323b8ba8-70f2-487b-a65e-9dcbda9b332a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04975204","created_at":"2021-07-23T13:52:34.611Z","updated_at":"2024-07-02T16:36:15.979Z","phase":"Phase 1","brief_title":"A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors","source_id_and_acronym":"NCT04975204","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TQB3909"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 02/18/2022","start_date":" 02/18/2022","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2022-03-07"}]